+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Readmission Rates of Patients with Schizophrenia Treated with Depot Antipsychotics versus Oral Antipsychotics in a Community Hospital



Readmission Rates of Patients with Schizophrenia Treated with Depot Antipsychotics versus Oral Antipsychotics in a Community Hospital



Cureus 10(12): E3775



This is a pilot study comparing the 30 and 60 day relapse rates for schizophrenic patients treated with long-acting injectable antipsychotics versus traditional oral antipsychotics in a community hospital setting. This is a retrospective cohort study and medical records were reviewed to gather data involving readmission rates. We analyzed the data using relative risk (RR) for the 30 days and 60 days after patient discharge from the behavioral health unit of a community hospital.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066544814

Download citation: RISBibTeXText

PMID: 30820394


Related references

Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics. Psychiatric Services 67(11): 1183-1188, 2016

Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics. Psychiatrische Praxis 34(6): 289-291, 2007

Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort Study. Iranian Journal of Psychiatry and Behavioral Sciences 8(1): 66-71, 2014

Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotics or Oral Antipsychotics for Schizophrenia. Psychiatric Services 58(4): 482-488, 2007

Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services 58(4): 482-488, 2007

Depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia. 2011

Perceptions on efficacy and side effects of conventional depot antipsychotics (CDA) and atypical depot antipsychotics (ADA): Psychiatrists versus patients in Hong Kong. International Journal of Psychiatry in Clinical Practice 14(1): 23-32, 2010

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. Journal of Clinical Psychiatry 74(6): 568-575, 2013

F75. Medication Adherence And Discontinuation In Patients With Schizophrenia Treated With Aripiprazole Once-Monthly Long-Acting Injectable Versus Those Treated With Oral Antipsychotics. Schizophrenia Bulletin 44(Suppl_1): S248-S249, 2018

Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder. Mental Health Clinician 6(5): 254-259, 2016

Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics. Psychiatry and Clinical Neurosciences 58(3): 268-273, 2004

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. Annals of General Psychiatry 16: 43, 2017

Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. Journal of Managed Care and Specialty Pharmacy 21(9): 754-768, 2015

How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?. European Neuropsychopharmacology 20(4): 276-279, 2010

Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics. Advances in Therapy 35(11): 1994-2014, 2018